Cargando…

Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice

Cyclophosphamide (CTX), a clinically important antineoplastic drug, also leads to some side effects such as nausea, vomiting and diarrhea in the consumer. In this study, Lactobacillus plantarum (L. plantarum) KLDS1.0318 preserved in our laboratory was orally administered to CTX-treated mice to explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Yueyue, Wang, Jing, Wang, Zhiyu, Zhang, Guofang, Liu, Libo, Huo, Guicheng, Li, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473033/
https://www.ncbi.nlm.nih.gov/pubmed/31031723
http://dx.doi.org/10.3389/fmicb.2019.00731
_version_ 1783412342189457408
author Meng, Yueyue
Wang, Jing
Wang, Zhiyu
Zhang, Guofang
Liu, Libo
Huo, Guicheng
Li, Chun
author_facet Meng, Yueyue
Wang, Jing
Wang, Zhiyu
Zhang, Guofang
Liu, Libo
Huo, Guicheng
Li, Chun
author_sort Meng, Yueyue
collection PubMed
description Cyclophosphamide (CTX), a clinically important antineoplastic drug, also leads to some side effects such as nausea, vomiting and diarrhea in the consumer. In this study, Lactobacillus plantarum (L. plantarum) KLDS1.0318 preserved in our laboratory was orally administered to CTX-treated mice to explore its potential effects to attenuate the toxic effects of CTX-induced by modulating intestinal immune response, promoting intestinal integrity and improving metabolic profile. BALB/c mice were randomly divided into six groups including normal control group (NC; non-CTX with sterile saline), model control group (MC; CTX-treated with sterile saline), CTX-treated with L. plantarum KLDS1.0318 (10 mL/kg) groups with three different doses (KLDS1.0318-L, 5 × 10(7) CFU/mL; KLDS1.0318-M, 5 × 10(8) CFU/mL; KLDS1.0318-H, 5 × 10(9) CFU/mL), and CTX-treated with levamisole hydrochloride (40 mg/kg) as a positive control (PC) group. After receiving the bacterium for 20 days, samples of small intestine and colonic contents were collected for different analyses. The results revealed that the levels of cytokines secreted by Th1 cells (IL-2, IFN-γ, and TNF-α) and Th2 cells (IL-4, IL-6, and IL-10) in probiotic treatment groups were significantly higher than those in the MC group. Histopathological results showed that L. plantarum KLDS1.0318 favorably recovered CTX-induced abnormal intestinal morphology by improving the villus height and crypt depth as well as quantity of goblet cells and mucins production. Compared to CTX alone-treated group, the production of short-chain fatty acids (SCFAs) were significantly increased and the levels of pH and ammonia were decreased significantly with high dose L. plantarum KLDS1.0318 supplementation. Compared with mice in CTX alone-treated group, mice in three groups of KLDS1.0318 had increased Bifidobacterium and Lactobacillus and decreased Escherichia and Enterococcus in their cecal content. The present findings suggested that L. plantarum KLDS1.0318 could be of significant advantage to mitigate the harmful effects of CTX and improve the intestinal health in mice.
format Online
Article
Text
id pubmed-6473033
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64730332019-04-26 Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice Meng, Yueyue Wang, Jing Wang, Zhiyu Zhang, Guofang Liu, Libo Huo, Guicheng Li, Chun Front Microbiol Microbiology Cyclophosphamide (CTX), a clinically important antineoplastic drug, also leads to some side effects such as nausea, vomiting and diarrhea in the consumer. In this study, Lactobacillus plantarum (L. plantarum) KLDS1.0318 preserved in our laboratory was orally administered to CTX-treated mice to explore its potential effects to attenuate the toxic effects of CTX-induced by modulating intestinal immune response, promoting intestinal integrity and improving metabolic profile. BALB/c mice were randomly divided into six groups including normal control group (NC; non-CTX with sterile saline), model control group (MC; CTX-treated with sterile saline), CTX-treated with L. plantarum KLDS1.0318 (10 mL/kg) groups with three different doses (KLDS1.0318-L, 5 × 10(7) CFU/mL; KLDS1.0318-M, 5 × 10(8) CFU/mL; KLDS1.0318-H, 5 × 10(9) CFU/mL), and CTX-treated with levamisole hydrochloride (40 mg/kg) as a positive control (PC) group. After receiving the bacterium for 20 days, samples of small intestine and colonic contents were collected for different analyses. The results revealed that the levels of cytokines secreted by Th1 cells (IL-2, IFN-γ, and TNF-α) and Th2 cells (IL-4, IL-6, and IL-10) in probiotic treatment groups were significantly higher than those in the MC group. Histopathological results showed that L. plantarum KLDS1.0318 favorably recovered CTX-induced abnormal intestinal morphology by improving the villus height and crypt depth as well as quantity of goblet cells and mucins production. Compared to CTX alone-treated group, the production of short-chain fatty acids (SCFAs) were significantly increased and the levels of pH and ammonia were decreased significantly with high dose L. plantarum KLDS1.0318 supplementation. Compared with mice in CTX alone-treated group, mice in three groups of KLDS1.0318 had increased Bifidobacterium and Lactobacillus and decreased Escherichia and Enterococcus in their cecal content. The present findings suggested that L. plantarum KLDS1.0318 could be of significant advantage to mitigate the harmful effects of CTX and improve the intestinal health in mice. Frontiers Media S.A. 2019-04-12 /pmc/articles/PMC6473033/ /pubmed/31031723 http://dx.doi.org/10.3389/fmicb.2019.00731 Text en Copyright © 2019 Meng, Wang, Wang, Zhang, Liu, Huo and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Meng, Yueyue
Wang, Jing
Wang, Zhiyu
Zhang, Guofang
Liu, Libo
Huo, Guicheng
Li, Chun
Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title_full Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title_fullStr Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title_full_unstemmed Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title_short Lactobacillus plantarum KLDS1.0318 Ameliorates Impaired Intestinal Immunity and Metabolic Disorders in Cyclophosphamide-Treated Mice
title_sort lactobacillus plantarum klds1.0318 ameliorates impaired intestinal immunity and metabolic disorders in cyclophosphamide-treated mice
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473033/
https://www.ncbi.nlm.nih.gov/pubmed/31031723
http://dx.doi.org/10.3389/fmicb.2019.00731
work_keys_str_mv AT mengyueyue lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT wangjing lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT wangzhiyu lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT zhangguofang lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT liulibo lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT huoguicheng lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice
AT lichun lactobacillusplantarumklds10318amelioratesimpairedintestinalimmunityandmetabolicdisordersincyclophosphamidetreatedmice